NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients
1. Kadimastem receives Hong Kong patent for IsletRx technology, enhancing IP protection. 2. The patent boosts global strategy for developing diabetes treatment via IsletRx. 3. Diabetes prevalence in Hong Kong estimated at 8.2%, impacting healthcare costs. 4. IsletRx aims to supply insulin-producing cells, addressing diabetes care challenges. 5. CEO emphasizes importance of strong IP in progressing towards clinical developments.